CoChat

Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma

Open access

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

The Wnt/β-catenin signaling is abnormally activated in the progression of hepatocellular carcinoma (HCC). BCL9 is an essential co-activator in the Wnt/β-catenin signaling. Importantly, BCL9 is absent from tumors originating from normal cellular counterparts and overexpressed in many cancers including HCC. But the mechanism for BCL9 overexpression remains unknown. Ample evidence indicates that hypoxia inducible factors (HIFs) play a role in the development of HCC. It was found in our study that BCL9 was overexpressed in both primary HCC and bone metastasis specimens; loss of BCL9 inhibited the proliferation, migration and angiogenesis of HCC; and that that hypoxia mechanically induced the expression of BCL9. BCL9 induction under the hypoxic condition was predominantly mediated by HIF-1α but not HIF2α. In vitro evidence from xenograft models indicated that BCL9 promoter/gene knockout inhibited HCC tumor growth and angiogenesis. Notably, we found that BCL9 and HIF-1α were coordinately regulated in human HCC specimen. The above findings suggest that hypoxia may promote the expression of BCL9 and associate with the development of HCC. Specific regulation of BCL9 expression by HIF-1α may prove to be an underlying crosstalk between Wnt/β-catenin signaling and hypoxia signaling pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep40446

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 BCL9 expression in primary and metastastic HCC tissue. Representative immunohistochemical stained imaging of BCL9 expression in different developing stages of HCC tissue containing 30 normal liver tissues, 360 primary HCC tissues and 72 bone metastatic HCC tissues. (A) No BCL9 staining in the normal mucosal epithelium; (B) low intensity expression in primary HCC tissue scored as negative (−); (C) moderate intensity expression in primary HCC tissue scored as weak (+); (D) high intensity expression in primary HCC tissue scored as strong (++); (E) BCL9 staining in bone metastatic HCC tissues. Scale bar: 40 μm for low magnitude image (10×); 10 μm for high magnitude images (40×).
Figure 1 BCL9 expression in primary and metastastic HCC tissue. Representative immunohistochemical stained imaging of BCL9 expression in different developing stages of HCC tissue containing 30 normal liver tissues, 360 primary HCC tissues and 72 bone metastatic HCC tissues. (A) No BCL9 staining in the normal mucosal epithelium; (B) low intensity expression in primary HCC tissue scored as negative (−); (C) moderate intensity expression in primary HCC tissue scored as weak (+); (D) high intensity expression in primary HCC tissue scored as strong (++); (E) BCL9 staining in bone metastatic HCC tissues. Scale bar: 40 μm for low magnitude image (10×); 10 μm for high magnitude images (40×).CC BY · PubMed Central
Figure 2 BCL9 promotes cell proliferation, migration, and angiogenesis. (A) Over-expression and knockdown BCL9 in HepG2 and smmc-7721 cell lines. (B) BCL9 over-expression significantly increases cell viability, while BCL9 knockdown reduces cell viability in HepG2 and smmc-7721 cell lines. (C) BCL9 over-expression significantly increases the cell migration ability, while BCL9 knockdown reduces the cell migration ability in HepG2 and smmc-7721 cell lines. (D) BCL9 over-expression significantly increases the angiogenesis activity, while BCL9 knockdown reduces the angiogenesis activity in HepG2 cell line. Data are presented as mean ± SD (n = 3). *: p < 0.01, Student’s t-test.
Figure 2 BCL9 promotes cell proliferation, migration, and angiogenesis. (A) Over-expression and knockdown BCL9 in HepG2 and smmc-7721 cell lines. (B) BCL9 over-expression significantly increases cell viability, while BCL9 knockdown reduces cell viability in HepG2 and smmc-7721 cell lines. (C) BCL9 over-expression significantly increases the cell migration ability, while BCL9 knockdown reduces the cell migration ability in HepG2 and smmc-7721 cell lines. (D) BCL9 over-expression significantly increases the angiogenesis activity, while BCL9 knockdown reduces the angiogenesis activity in HepG2 cell line. Data are presented as mean ± SD (n = 3). *: p < 0.01, Student’s t-test.CC BY · PubMed Central
Figure 3 Hypoxia induces BCL9 expression in HCC cells. Human HCC cell lines HepG2 and SMMC-7721 cells were cultured under the hypoxic condition for the indicated time periods. (A) The mRNA expression levels of BCL9 in these cells were determined by Taqman real-time PCR and normalized with actin. (B) The mRNA expression levels of VEGF in these cells were determined as a positive control. (C) The BCL9, HIF-1α and HIF-2α protein levels were determined by Western-blot assays. (D) Significant increase in TOPflash activity was observed under hypoxia treatment. Further, the TOPflash activity was significantly increased when BCL9 overexpressed while decreased when BCL9 knocked down. Data are presented as mean ± SD (n = 3).*p < 0.01, Student’s t-test.
Figure 3 Hypoxia induces BCL9 expression in HCC cells. Human HCC cell lines HepG2 and SMMC-7721 cells were cultured under the hypoxic condition for the indicated time periods. (A) The mRNA expression levels of BCL9 in these cells were determined by Taqman real-time PCR and normalized with actin. (B) The mRNA expression levels of VEGF in these cells were determined as a positive control. (C) The BCL9, HIF-1α and HIF-2α protein levels were determined by Western-blot assays. (D) Significant increase in TOPflash activity was observed under hypoxia treatment. Further, the TOPflash activity was significantly increased when BCL9 overexpressed while decreased when BCL9 knocked down. Data are presented as mean ± SD (n = 3).*p < 0.01, Student’s t-test.CC BY · PubMed Central
Figure 4 Hypoxia transactivates hypoxia-responsive elements (HREs) in the BCL9 promoter which transcriptionally regulated by HIF-1α. (A) The human BCL9 gene contains 3 putative HREs in its promoter region. (B) Hypoxia activates the luciferase activity of reporter vectors containing HRE-B or HRE-C sites in the BCL9 promoter. HepG2 and SMMC-7721 cells were transfected with the luciferase reporter vectors, and then subjected to hypoxia treatment for 36 h before measuring luciferase activities. Luciferase reporter vectors containing the HRE site in the VEGF promoter was included as a positive control. (C,D) HIF-1α but not HIF-2α binds to HRE-B and HRE-C sites in the BCL9 promoter under the hypoxic condition in HepG2 cells as determined by ChIP assays. Cells were cultured under the hypoxic or normoxic conditions for 36 h before assays. The HRE site in the VEGF promoter serves as a positive control. The amount of DNA fragments pulled- down was determined by real-time PCR (C) or conventional PCR (D). (E) Ectopic HIF-1α expression increases BCL9 protein levels in HepG2 cells as determined by Western-blot assays. (F,G) HIF-1α binds to HRE-B and HRE-C sites in the BCL9 promoter in HepG2 cells transfected with HIF-1α expression plasmids as determined by ChIP assays. The amount of DNA fragments pulled-down was determined by real-time PCR (F) or conventional PCR (F). The HRE site in the VEGF promoter serves as a positive control. Data are presented as mean ± SD (n = 3). *p < 0.01 (Student’s t-test).
Figure 4 Hypoxia transactivates hypoxia-responsive elements (HREs) in the BCL9 promoter which transcriptionally regulated by HIF-1α. (A) The human BCL9 gene contains 3 putative HREs in its promoter region. (B) Hypoxia activates the luciferase activity of reporter vectors containing HRE-B or HRE-C sites in the BCL9 promoter. HepG2 and SMMC-7721 cells were transfected with the luciferase reporter vectors, and then subjected to hypoxia treatment for 36 h before measuring luciferase activities. Luciferase reporter vectors containing the HRE site in the VEGF promoter was included as a positive control. (C,D) HIF-1α but not HIF-2α binds to HRE-B and HRE-C sites in the BCL9 promoter under the hypoxic condition in HepG2 cells as determined by ChIP assays. Cells were cultured under the hypoxic or normoxic conditions for 36 h before assays. The HRE site in the VEGF promoter serves as a positive control. The amount of DNA fragments pulled- down was determined by real-time PCR (C) or conventional PCR (D). (E) Ectopic HIF-1α expression increases BCL9 protein levels in HepG2 cells as determined by Western-blot assays. (F,G) HIF-1α binds to HRE-B and HRE-C sites in the BCL9 promoter in HepG2 cells transfected with HIF-1α expression plasmids as determined by ChIP assays. The amount of DNA fragments pulled-down was determined by real-time PCR (F) or conventional PCR (F). The HRE site in the VEGF promoter serves as a positive control. Data are presented as mean ± SD (n = 3). *p < 0.01 (Student’s t-test).CC BY · PubMed Central
Figure 5 Genetic engineering of HepG2 cells using TALENs. (A) Schematic overview depicting the targeting strategy for BCL9 promoter. Primers are shown as red boxes; the blue arrow indicates the cut site by the TALENs. Donor plasmids: CMV promoter, human cytomegalovirus (CMV) immediate early promoter gene; eGFP, enhanced green fluorescent protein gene; Below, scheme of BCL9 TALENs and their recognition sequence. TALE repeat domains are colored to indicate the identity of the repeat variable diresidue (RVD); each RVD is related to the cognate targeted DNA base by the following code (N1 = A, HD = C, NN = G, NG = T). (B) Genomic PCR and restriction digestion characterization of BCL9-p-ko HepG2 cells. (C) Different TALEN pairs were designed. (D) The activities of each two TALEN constructs were examined by SSA assay, and construct L1-R1 showed the highest activity among the constructs in the assay. (E) The genomic sequences around the target site of the clones were detected. (F) BCL9-wt, BCL9-p-ko and BCL9-ko HepG2 cells were cultured under the hypoxic condition. The BCL9 and HIF-1α protein levels were determined by Western-blot assays. Data are presented as mean ± SD (n = 3). *p < 0.01, Student’s t-test.
Figure 5 Genetic engineering of HepG2 cells using TALENs. (A) Schematic overview depicting the targeting strategy for BCL9 promoter. Primers are shown as red boxes; the blue arrow indicates the cut site by the TALENs. Donor plasmids: CMV promoter, human cytomegalovirus (CMV) immediate early promoter gene; eGFP, enhanced green fluorescent protein gene; Below, scheme of BCL9 TALENs and their recognition sequence. TALE repeat domains are colored to indicate the identity of the repeat variable diresidue (RVD); each RVD is related to the cognate targeted DNA base by the following code (N1 = A, HD = C, NN = G, NG = T). (B) Genomic PCR and restriction digestion characterization of BCL9-p-ko HepG2 cells. (C) Different TALEN pairs were designed. (D) The activities of each two TALEN constructs were examined by SSA assay, and construct L1-R1 showed the highest activity among the constructs in the assay. (E) The genomic sequences around the target site of the clones were detected. (F) BCL9-wt, BCL9-p-ko and BCL9-ko HepG2 cells were cultured under the hypoxic condition. The BCL9 and HIF-1α protein levels were determined by Western-blot assays. Data are presented as mean ± SD (n = 3). *p < 0.01, Student’s t-test.CC BY · PubMed Central
Figure 6 BCL9 promotes the tumor growth in vivo. (A) The HepG2 cells infected with BCL9-wt, BCL9-p-ko and BCL9-ko were injected subcutaneously into the nude mice. (B) Mice were sacrificed to remove the tumors, and images were taken with a Nikon camera. (C) Tumor weight was evaluate among BCL9-wt, BCL9-p-ko and BCL9-ko group. (D) HIF-1α (red) and BCL9 (green) detected by FISH and IF in tumors: HIF-1α normally expressed in BCL9-wt, BCL9-p-ko and BCL9-ko groups; BCL9 normally expressed in BCL9-wt, weakly expressed in BCL9-p-ko group and unexpressed in BCL9-ko group. (E,F) Angiogenesis was detected by IHC and RT-PCR: angiogenesis was significantly decreased in BCL9-p-ko and BCL9-ko group. (G) WNT/β-catenin target genes, including CD44, Axin-2 and Survivin, were detected by RT-PCR. CD44, Axin-2 and Survivin were significantly decreased in BCL9-p-ko and BCL9-ko group. Data are presented as mean ± SD (n = 3). *p < 0.01, Student’s t-test.
Figure 6 BCL9 promotes the tumor growth in vivo. (A) The HepG2 cells infected with BCL9-wt, BCL9-p-ko and BCL9-ko were injected subcutaneously into the nude mice. (B) Mice were sacrificed to remove the tumors, and images were taken with a Nikon camera. (C) Tumor weight was evaluate among BCL9-wt, BCL9-p-ko and BCL9-ko group. (D) HIF-1α (red) and BCL9 (green) detected by FISH and IF in tumors: HIF-1α normally expressed in BCL9-wt, BCL9-p-ko and BCL9-ko groups; BCL9 normally expressed in BCL9-wt, weakly expressed in BCL9-p-ko group and unexpressed in BCL9-ko group. (E,F) Angiogenesis was detected by IHC and RT-PCR: angiogenesis was significantly decreased in BCL9-p-ko and BCL9-ko group. (G) WNT/β-catenin target genes, including CD44, Axin-2 and Survivin, were detected by RT-PCR. CD44, Axin-2 and Survivin were significantly decreased in BCL9-p-ko and BCL9-ko group. Data are presented as mean ± SD (n = 3). *p < 0.01, Student’s t-test.CC BY · PubMed Central
Figure 7 HIF-1α overexpression is associated with BCL9 overexpression in human HCC. HIF-1α and BCL9 protein levels were detected by IHC staining in tissue microarrays containing 488 cases of human HCC specimens. (A) HIF-1α (red) and BCL9 (green) detected by FISH and IF in human HCC specimens. (B) HIF-1α overexpression is associated with BCL9 overexpression in human HCC (p < 0.000, Fisher exact test).
Figure 7 HIF-1α overexpression is associated with BCL9 overexpression in human HCC. HIF-1α and BCL9 protein levels were detected by IHC staining in tissue microarrays containing 488 cases of human HCC specimens. (A) HIF-1α (red) and BCL9 (green) detected by FISH and IF in human HCC specimens. (B) HIF-1α overexpression is associated with BCL9 overexpression in human HCC (p < 0.000, Fisher exact test).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 100

Metadata

Authors
Xu, W., Zhou, W., Cheng, M., Wang, J., Liu, Z., He, S., Luo, X., Huang, W., Chen, T., Yan, W., & Xiao, J.
Affiliations
  • Second Military Medical University (CN)
  • Xuzhou Medical College (CN)
  • Fudan University (CN)
Corresponding author
  • Chen, Tianrui
  • Yan, Wangjun
  • Xiao, Jianru
Venue
Scientific Reports
Published
2017-01-11
Volume
7
Issue
1
Pages
40446-40446
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2572807950
Cited by
85
References
51
Citations by year
2026: 1 · 2025: 8 · 2024: 8 · 2023: 8 · 2022: 10 · 2021: 12 · 2020: 11 · 2019: 12 · 2018: 9 · 2017: 6
FWCI
4.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81572746, 81201556, 81372874)
  • China Postdoctoral Science Foundation (43302)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
hepatocellular carcinoma, hypoxia, Wnt/β-catenin signaling, BCL9, HIF-1α, HIF-2α, tumor hypoxia, bone metastasis, tumor angiogenesis, cell proliferation and migration, signaling crosstalk
MeSH terms
Transcription Activator-Like Effector Nucleases, Endothelial PAS Domain-Containing Protein 1, Adult, Animals, Base Sequence, Bone Neoplasms, Cell Movement, Female, Genetic Engineering, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Mice, Nude, Middle Aged, Neoplasm Proteins, Neovascularization, Pathologic, Promoter Regions, Genetic, Transcription Factors, Transcriptional Activation, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Response Elements, Cell Proliferation, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit, Hep G2 Cells, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. https://app.cochat.ai/papers/10.1038/srep40446
The paper
Xu, W., Zhou, W., Cheng, M., Wang, J., Liu, Z., He, S., Luo, X., Huang, W., Chen, T., Yan, W., & Xiao, J. (2017). Hypoxia activates Wnt/β-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Scientific Reports. https://doi.org/10.1038/srep40446

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.